RA CAPITAL MANAGEMENT, L.P. Insider Trading -- Recent SEC Form 4 Transactions

RA CAPITAL MANAGEMENT, L.P. (CIK 1346824) reported 191 SEC Form 4 insider transactions across 22 companies over the past 18 months (most recent 2026-06-22). Recent activity: Sell HOWL (389,216 shares), Sell HOWL (27,695 shares), Buy COAG (6,146 shares), Buy COAG (61,523 shares), Sell HOWL (9,939 shares). Source: SEC Form 4.

DateCompanyRoleTypeSharesValue
2026-06-22Werewolf Therapeutics, Inc. (HOWL)InsiderSell389,216$136,226
2026-06-22Werewolf Therapeutics, Inc. (HOWL)InsiderSell27,695$9,693
2026-06-17Hemab Therapeutics Holdings, Inc. (COAG)InsiderBuy6,146$152,974
2026-06-17Hemab Therapeutics Holdings, Inc. (COAG)InsiderBuy61,523$1.5M
2026-06-16Werewolf Therapeutics, Inc. (HOWL)InsiderSell9,939$3,677
2026-06-16Werewolf Therapeutics, Inc. (HOWL)InsiderSell159,119$63,648
2026-06-16Artiva Biotherapeutics, Inc. (ARTV)DirectorBuy15,414$138,572
2026-06-16Werewolf Therapeutics, Inc. (HOWL)InsiderSell11,322$4,529
2026-06-16Artiva Biotherapeutics, Inc. (ARTV)DirectorBuy124,893$1.1M
2026-06-16Werewolf Therapeutics, Inc. (HOWL)InsiderSell120,216$46,884
2026-06-16Werewolf Therapeutics, Inc. (HOWL)InsiderSell8,554$3,336
2026-06-16Werewolf Therapeutics, Inc. (HOWL)InsiderSell139,686$51,684
2026-06-16Artiva Biotherapeutics, Inc. (ARTV)DirectorBuy391,019$3.4M
2026-06-12Janux Therapeutics, Inc. (JANX)DirectorBuy5,500$0
2026-06-11Artiva Biotherapeutics, Inc. (ARTV)DirectorBuy479,039$3.3M
2026-06-11Werewolf Therapeutics, Inc. (HOWL)InsiderSell345,235$127,737
2026-06-11Artiva Biotherapeutics, Inc. (ARTV)DirectorBuy103$721
2026-06-11Werewolf Therapeutics, Inc. (HOWL)InsiderSell24,565$9,089
2026-06-11Artiva Biotherapeutics, Inc. (ARTV)DirectorBuy548,580$4.3M
2026-06-11Werewolf Therapeutics, Inc. (HOWL)InsiderSell42,872$15,863
2026-06-11Werewolf Therapeutics, Inc. (HOWL)InsiderSell3,051$1,129
2026-06-11Werewolf Therapeutics, Inc. (HOWL)InsiderSell245,066$93,125
2026-06-11Werewolf Therapeutics, Inc. (HOWL)InsiderSell17,437$6,626
2026-06-05Acumen Pharmaceuticals, Inc. (ABOS)DirectorBuy35,500$0
2026-05-21Hemab Therapeutics Holdings, Inc. (COAG)InsiderBuy3,802$94,936

Source: SEC Form 4 filings · as of 2026-06-22